Interesting Doc, but Dr. Liau was interviewed by a former patient recently and stated that NWBO was in charge of trial completion -- not her. If the reference to Dr. Liau instead means we must wait until SNO ( Since that is her turf), I'd imagine that is highly unnecessary regarding topline. The endpoints go through four year survival. Four year KM is already set in stone. Limiting factor is either SAP responses from regulators, or perhaps NWBO buying time, imo.